Core Viewpoint - The company anticipates a significant decline in net profit for the first half of 2025, primarily due to intensified industry competition and a lagging effect from the overall downturn in the real estate market [1] Group 1: Profit Warning - The company issued a profit warning on August 8, indicating that the net profit attributable to shareholders for the first half of 2025 is expected to decrease by approximately 40% to 50% compared to about RMB 5.01 billion in the same period of 2024 [1] - The anticipated decline in profit is attributed to increased competition in the industry and the lagging effects of the overall downturn in the real estate market, leading to a decrease in overall project revenue [1] Group 2: Business Growth - Despite the challenging market conditions, the company experienced strong growth in new construction management projects, with a total contracted construction area of 19.89 million square meters, representing an increase of approximately 13.9% year-on-year [1] - The estimated management fees for new construction projects are projected to be around RMB 5 billion, reflecting a year-on-year growth of approximately 19.1% [1] - The company has seen an increase in the proportion of commercial construction management and repeat commissioning rates, demonstrating its strong expansion capabilities and customer trust even under market pressure, which will contribute to performance certainty and lay a foundation for sustainable high-quality development [1]

Core Viewpoint - 康耐特光学 reported a revenue of RMB 1.084 billion for the six months ending June 30, 2025, representing a year-on-year increase of 11.04% [1] - The profit attributable to the owners of the parent company was RMB 273 million, an increase of 30.73% year-on-year [1] - The company proposed an interim dividend of RMB 0.15 per ordinary share (tax included) [1] Revenue and Profit Growth - The increase in revenue and profit is attributed to the orderly expansion of both international and domestic businesses [1] - Sales of high value-added products have shown stable growth [1] - Upgrades to automated production lines have effectively improved production and labor efficiency while reducing production costs [1]

加密货币为数字货币，其中采用加密技术规范货币单位的产生及采用区块链技术验证资金的转移。加密 货币使交易双方之间的资金转移更为容易，为确保安全，该等转移乃通过使用公钥及私钥进行。集团认 为加密货币作为一种价值储存方式，具有强大的公共开源架构的支持，故从长远来看，其具有抗通胀的 潜力，使储存的价值升值及具有长期价值。集团亦注意到，加密货币的价格或会大幅波动，故集团拟投 资于市场上更为成熟且获广泛认可、市场流动性佳、市值较大，并具有相对长期持有价值的加密货币。 智通财经APP讯，国际商业结算(00147)发布公告，于2025年8月8日，公司全资附属公司成泰与陈三明先 生就成立合营企业订立合营协议，于注册成立后，合营企业将由成泰及陈三明先生分别拥有70%及30% 权益。合营企业将主要从事加密资产相关业务。 此外，董事会认为，加密货币市场具有良好的发展前景。成立合营企业符合集团发展金融科技产业的业 务发展策略及计划，从而将有利于集团未来的业务发展。董事会认为，合营企业为集团提供良机，将业 务范围拓展至加密货币市场及使集团的收入来源多元化。 ...

公告称，收入增长主要受于2025年3月获国家药监局批准的恶性狭窄冷冻消融系统及冷冻粘连治疗系统 等呼吸介入产品的销量增加所带动。此外，波科国际医疗贸易(上海)有限公司的其他呼吸介入产品的经 销销售于报告期间相应增加。亏损收窄是由于公司优化发展策略并实施集团控制开支的有效措施。 智通财经APP讯，康沣生物-B(06922)公布2025年中期业绩，收入5110.6万元，同比增长约1.62倍;毛利 3431.2万元，同比增长约1.25倍;母公司拥有人应占亏损2381.7万元，同比收窄54.35%;每股亏损0.1元。 ...

Core Viewpoint - 康耐特光学 reported a revenue of RMB 1.084 billion for the six months ending June 30, 2025, representing an increase of 11.04% year-on-year [1] - The profit attributable to the owners of the parent company was RMB 273 million, reflecting a year-on-year increase of 30.73% [1] - The company proposed an interim dividend of RMB 0.15 per ordinary share (tax included) [1] Revenue and Profit Growth - The increase in revenue and profit was primarily due to the orderly expansion of both international and domestic businesses [1] - Sales of high value-added products showed stable growth [1] - Upgrades to automated production lines effectively improved production and labor efficiency while reducing production costs [1]

为保障战略委员会和风险委员会工作有序开展，经战略委员会、风险委员会各自过半数委员共同推举， 在各自主任委员缺位情况下，分别由执行董事孔庆龙先生代为履行战略委员会主任委员职责，由非执行 董事卢浩先生代为履行风险委员会主任委员职责。 徽商银行(03698)发布公告，有关(其中包括)严琛先生辞任该行董事长、执行董事、发展战略与消费者权 益保护委员会(战略委员会)主任委员及委员、风险管理委员会(风险委员会)主任委员及委员、人事提名 和薪酬委员会委员职务。 ...

Core Viewpoint - The company expects to report a loss attributable to shareholders of no more than HKD 535 million for the six months ending June 30, 2025, compared to a profit of approximately HKD 150.5 million in the same period last year, primarily due to a fair value loss on convertible bonds of about HKD 497.9 million [1] Financial Performance - The anticipated loss for the upcoming period is significantly higher than the previous year's profit, indicating a substantial decline in financial performance [1] - The fair value loss on convertible bonds is a major contributor to the expected increase in losses [1] Accounting Adjustments - The board emphasizes that the fair value loss is a non-cash accounting adjustment, which does not involve any cash outflow and does not reflect the underlying core operating performance of the company [1] - The loss is attributed to the application and compliance with relevant accounting standards [1]

康沣生物-B(06922)公布2025年中期业绩，收入5110.6万元，同比增长约1.62倍;毛利3431.2万元，同比增 长约1.25倍;母公司拥有人应占亏损2381.7万元，同比收窄54.35%;每股亏损0.1元。 公告称，收入增长主要受于2025年3月获国家药监局批准的恶性狭窄冷冻消融系统及冷冻粘连治疗系统 等呼吸介入产品的销量增加所带动。此外，波科国际医疗贸易(上海)有限公司的其他呼吸介入产品的经 销销售于报告期间相应增加。亏损收窄是由于公司优化发展策略并实施集团控制开支的有效措施。 ...

格隆汇8月8日丨康沣生物-B(06922.HK)发布公告，截至2025年6月30日止六个月，公司的收入增加至人 民币51.1百万元，同比增幅为162.4%，主要受于2025年3月获国家药监局批准的恶性狭窄冷冻消融系统 及冷冻粘连治疗系统等呼吸介入产品的销量增加所带动。此外，波科国际医疗贸易（上海）有限公司的 其他呼吸介入产品的经销销售于报告期间相应增加。 报告期间的亏损由截至2024年6月30日止六个月的的人民币56.0百万元减少至截至2025年6月30日止六个 月的人民币27.2百万元，大幅减少人民币28.8百万元，减幅为51.4%，由于公司优化发展策略并实施集 团控制开支的有效措施。 ...

格隆汇8月8日丨国际商业结算(00147.HK)发布公告，于2025年8月8日，公司全资附属公司成泰与陈三明 先生就成立合营企业订立合营协议，于注册成立后，合营企业将由成泰及陈先生分别拥有70%及30%权 益。合营企业将主要从事加密资产相关业务。 根据合营协议，成泰及陈先生将分别注资70港元及30港元作为注册资金，且成泰及陈先生将分别向合营 企业提供本金为70百万港元及30百万港元的无息股东贷款，以发展及经营其业务。 董事会认为，加密货币市场具有良好的发展前景。成立合营企业符合集团发展金融科技产业的业务发展 策略及计划，从而将有利于集团未来的业务发展。董事会认为，合营企业为集团提供良机，将业务范围 拓展至加密货币市场及使集团的收入来源多元化。 ...